January 12th, Malaysia Pharmaceutical Group Fama signed an agreement with China Kexing Biotechnology to buy a coronavirus vaccine.
Malaysia plans to purchase 14 million doses of Kelifo coronavirus vaccine developed by Kexing Biotechnology.
The signing ceremony was held by video on the same day.
Youthorpe, managing director of Fama Company, said that under the agreement, Koxing Biotechnology will provide Malaysia with semi-finished vaccine products, which will be filled, produced and distributed locally by Fama Company.
At present, the company has discussed vaccine approval and registration with the National Drug Administration (NPRA) of Malaysia, and plans to distribute the vaccine to local hospitals by the end of March this year.